比替格拉韦、恩曲他滨和替诺福韦阿拉那胺与利托那韦增强的基于蛋白酶抑制剂的抗逆转录病毒治疗和海地二线治疗的病毒抑制：一项开放标签、随机、非劣效性试验

IF 13 1区医学 Q1 IMMUNOLOGY

Lancet Hiv Pub Date : 2025-08-27 DOI:10.1016/s2352-3018(25)00130-4

Patrice Severe MD, Samuel Pierre MD, Fabienne Homeus MD, Jean Bernard Marc MD, Letizia Trevisi PhD, Maria Linda Aristhomene BS, Guirlaine R Bernadin BS, Kerlyne Lavoile BS, Vanessa Rivera BS, Carl Frederic Duchatellier MD, Marie Josee Joseph BS, John Wu MBA, Vanessa Rouzier MD, Fabiola Preval BS, Evens Jean BS, Jodany Bernadin BS, Abigail Zion BS, Guyrlaine Pierre Louis Forestal PharmD, Santiago Avila-Rios PhD, Claudia Garcia Morales PhD, Adina Zhang MS, Dennis Israelski MD, Alexandra Apollon BS, Emelyne Dumont BS, Elizabeth Fox PhD, Pierre-Yves Cremieux PhD, Prof Jean W Pape MD, Sean E Collins MD, Bernard Liautaud MD, Prof Paul E Sax MD, Serena P Koenig MD

{"title":"比替格拉韦、恩曲他滨和替诺福韦阿拉那胺与利托那韦增强的基于蛋白酶抑制剂的抗逆转录病毒治疗和海地二线治疗的病毒抑制：一项开放标签、随机、非劣效性试验","authors":"Patrice Severe MD, Samuel Pierre MD, Fabienne Homeus MD, Jean Bernard Marc MD, Letizia Trevisi PhD, Maria Linda Aristhomene BS, Guirlaine R Bernadin BS, Kerlyne Lavoile BS, Vanessa Rivera BS, Carl Frederic Duchatellier MD, Marie Josee Joseph BS, John Wu MBA, Vanessa Rouzier MD, Fabiola Preval BS, Evens Jean BS, Jodany Bernadin BS, Abigail Zion BS, Guyrlaine Pierre Louis Forestal PharmD, Santiago Avila-Rios PhD, Claudia Garcia Morales PhD, Adina Zhang MS, Dennis Israelski MD, Alexandra Apollon BS, Emelyne Dumont BS, Elizabeth Fox PhD, Pierre-Yves Cremieux PhD, Prof Jean W Pape MD, Sean E Collins MD, Bernard Liautaud MD, Prof Paul E Sax MD, Serena P Koenig MD","doi":"10.1016/s2352-3018(25)00130-4","DOIUrl":null,"url":null,"abstract":"Patients on second-line protease inhibitor-based regimens in low-income and middle-income countries have high rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance, but access to testing is scarce. We aimed to assess the efficacy of combination oral bictegravir, emtricitabine, and tenofovir alafenamide in this population.","PeriodicalId":48725,"journal":{"name":"Lancet Hiv","volume":"33 1","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial\",\"authors\":\"Patrice Severe MD, Samuel Pierre MD, Fabienne Homeus MD, Jean Bernard Marc MD, Letizia Trevisi PhD, Maria Linda Aristhomene BS, Guirlaine R Bernadin BS, Kerlyne Lavoile BS, Vanessa Rivera BS, Carl Frederic Duchatellier MD, Marie Josee Joseph BS, John Wu MBA, Vanessa Rouzier MD, Fabiola Preval BS, Evens Jean BS, Jodany Bernadin BS, Abigail Zion BS, Guyrlaine Pierre Louis Forestal PharmD, Santiago Avila-Rios PhD, Claudia Garcia Morales PhD, Adina Zhang MS, Dennis Israelski MD, Alexandra Apollon BS, Emelyne Dumont BS, Elizabeth Fox PhD, Pierre-Yves Cremieux PhD, Prof Jean W Pape MD, Sean E Collins MD, Bernard Liautaud MD, Prof Paul E Sax MD, Serena P Koenig MD\",\"doi\":\"10.1016/s2352-3018(25)00130-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Patients on second-line protease inhibitor-based regimens in low-income and middle-income countries have high rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance, but access to testing is scarce. We aimed to assess the efficacy of combination oral bictegravir, emtricitabine, and tenofovir alafenamide in this population.\",\"PeriodicalId\":48725,\"journal\":{\"name\":\"Lancet Hiv\",\"volume\":\"33 1\",\"pages\":\"\"},\"PeriodicalIF\":13.0000,\"publicationDate\":\"2025-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Hiv\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s2352-3018(25)00130-4\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Hiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2352-3018(25)00130-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在低收入和中等收入国家，接受基于蛋白酶抑制剂的二线治疗方案的患者对核苷逆转录酶抑制剂（NRTI）的耐药率很高，但获得检测的机会很少。我们的目的是评估口服比替格拉韦、恩曲他滨和替诺福韦在这一人群中的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Bictegravir, emtricitabine, and tenofovir alafenamide versus ritonavir-boosted protease inhibitor-based antiretroviral therapy in people with HIV and viral suppression on second-line therapy in Haiti: an open-label, randomised, non-inferiority trial

Patients on second-line protease inhibitor-based regimens in low-income and middle-income countries have high rates of nucleoside reverse transcriptase inhibitor (NRTI) resistance, but access to testing is scarce. We aimed to assess the efficacy of combination oral bictegravir, emtricitabine, and tenofovir alafenamide in this population.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Lancet Hiv IMMUNOLOGYINFECTIOUS DISEASES&-INFECTIOUS DISEASES

CiteScore

19.90

自引率

4.30%

发文量

368

期刊介绍： The Lancet HIV is an internationally trusted source of clinical, public health, and global health knowledge with an Impact Factor of 16.1. It is dedicated to publishing original research, evidence-based reviews, and insightful features that advocate for change in or illuminates HIV clinical practice. The journal aims to provide a holistic view of the pandemic, covering clinical, epidemiological, and operational disciplines. It publishes content on innovative treatments and the biological research behind them, novel methods of service delivery, and new approaches to confronting HIV/AIDS worldwide. The Lancet HIV publishes various types of content including articles, reviews, comments, correspondences, and viewpoints. It also publishes series that aim to shape and drive positive change in clinical practice and health policy in areas of need in HIV. The journal is indexed by several abstracting and indexing services, including Crossref, Embase, Essential Science Indicators, MEDLINE, PubMed, SCIE and Scopus.